The ICS assay can be performed using cryopreserved peripheral blood mononuclear cells (PBMCs) (Horton

et al., 2007) or fresh whole blood (Hanekom et al., 2004 and Meddows-Taylor Quizartinib datasheet et al., 2007). The reliable evaluation of CMI responses requires cell samples that have been properly prepared. That implies cell samples of good quality, regularly assessed for the proportion of viable lymphocytes in the sample before flow cytometry analysis. Previously, it was shown that the length of time from venipuncture to cryopreservation was the most important parameter influencing T-cell performance in cellular immune assays, affecting subsequent cell recovery and function (Bull et al., 2007). Recent observations indicate that several other parameters involved in click here blood processing as well as antigen-stimulation can impact cell viability and the measured T-cell responses (Owen et al., 2007, Jeurink et al., 2008, McKenna et al., 2009, Weinberg et al., 2009, Afonso et al., 2010, Mallone

et al., 2011 and Kutscher et al., 2013). Moreover, the sensitivity of whole blood versus PBMC assays is still under debate, with different studies reaching opposite conclusions (Suni et al., 1998 and Hoffmeister et al., 2003). In recent HIV-1 vaccine trials, HIV-1-specific CD4+ and CD8+ T-cell responses were evaluated by ICS following in vitro stimulation with p17, p24, reverse transcriptase (RT) and Nef peptide pools to assess the expression of interleukin-2 (IL-2), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α) and CD40-ligand (CD40L), using PBMCs isolated from venous blood (Van Braeckel et al., 2011 and Harrer et al., 2014). By compiling previous evaluations, we observed a lower PBMC viability after ICS in antiretroviral therapy second (ART)-naïve HIV-1-infected patients (ART− HIV+) compared to ART-experienced

HIV-1-infected patients (ART+ HIV+) (samples from trial published in Harrer et al., 2014) or uninfected volunteers (HIV−) (samples from trial published in Denny et al., 2013) (Fig. 1). To investigate this further, blood samples were collected from ART− HIV+ patients and the following parameters were investigated: (i) time between blood collection and processing or cryopreservation of PBMCs (“time-to-process”); (ii) time between PBMC thawing and initiation of the in vitro stimulation (“resting-time”); and (iii) duration of antigen-stimulation in PBMC cultures (“stimulation-time”). The total cell recovery, cell viability and the magnitude or quality of HIV-specific T-cell responses were assessed to determine the optimal combination of process conditions. Additionally, the influence of the “time-to-process” parameter was evaluated following ICS on fresh whole blood samples. This was a phase I, self-contained clinical trial conducted at the Center for Vaccinology, Ghent University Hospital, Ghent, Belgium, between June and October 2012. Blood samples were collected from 22 ART− HIV+ adult participants.